Clinical trial
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
NCT06449313
Study timeline
Study start (estimated)2026-11-01Date precision: month
Registry last updated2026-10-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancer Stage IIIunresolved
Interventions
Cemiplimab-RwlcDRUG · verified · RxNorm: cemiplimab-rwlc
Sponsors & collaborators
Georgetown Universitylead sponsor
Regeneron Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06449313 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.